Talon Therapeutics is a biopharmaceutical company committed to identifying and seizing medical opportunities, expertly leading product candidates through clinical development and passing on value to patients, patient care providers, shareholders, corporate partners, and employees. Marqibo is the company’s lead asset, planned to replace standard vincristine chemotherapy. Talon Therapeutics’ other pipeline opportunities also have the potential to improve the delivery and therapeutic benefits of well-characterized, proven chemotherapies – enabling high potency doses without increasing toxicity. For more information, visit the company’s Web site at www.talontx.com

ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com

Let us hear your thoughts below: